NasdaqCM - Delayed Quote USD

Genenta Science S.p.A. (GNTA)

4.3400
+0.2400
+(5.85%)
At close: May 9 at 4:00:00 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
9,764.3100
9,764.3100
11,732.9420
11,043.9920
5,537.2730
Operating Income
-9,764.3100
-9,764.3100
-11,732.9420
-11,043.9920
-5,537.2730
Net Non Operating Interest Income Expense
81.1400
81.1400
309.2530
36.9850
-11.7160
Other Income Expense
770.6750
770.6750
-221.7660
2,529.2440
19.6570
Pretax Income
-8,912.4950
-8,912.4950
-11,645.4550
-8,477.7630
-5,529.3320
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-8,912.4950
-8,912.4950
-11,645.4550
-8,477.7630
-5,529.3320
Diluted NI Available to Com Stockholders
-8,912.4950
-8,912.4950
-11,645.4550
-8,477.7630
-5,529.3320
Basic EPS
-0.49
-0.49
-0.64
-0.47
-0.37
Diluted EPS
-0.49
-0.49
-0.64
-0.47
-0.37
Basic Average Shares
18,273.4900
18,273.4900
18,216.9070
18,216.8580
15,083.8250
Diluted Average Shares
18,273.4900
18,273.4900
18,216.9070
18,216.8580
15,083.8250
Total Operating Income as Reported
-9,764.3100
-9,764.3100
-11,732.9420
-11,043.9920
-5,687.2730
Total Expenses
9,764.3100
9,764.3100
11,732.9420
11,043.9920
5,537.2730
Net Income from Continuing & Discontinued Operation
-8,912.4950
-8,912.4950
-11,645.4550
-8,477.7630
-5,529.3320
Normalized Income
-9,153.4870
-9,153.4870
-11,428.5640
-10,764.4530
-5,529.3320
Interest Income
81.1400
81.1400
309.2530
36.9850
-11.7160
Interest Expense
--
--
--
--
11.7160
Net Interest Income
81.1400
81.1400
309.2530
36.9850
-11.7160
EBIT
-9,764.3100
-9,764.3100
-11,732.9420
-11,043.9920
-5,537.2730
EBITDA
-9,719.7870
-9,719.7870
-11,690.4890
-11,037.8520
-5,532.3840
Reconciled Depreciation
44.5230
44.5230
42.4530
6.1400
4.8890
Net Income from Continuing Operation Net Minority Interest
-8,912.4950
-8,912.4950
-11,645.4550
-8,477.7630
-5,529.3320
Total Unusual Items Excluding Goodwill
240.9920
240.9920
-216.8910
2,286.6900
--
Total Unusual Items
240.9920
240.9920
-216.8910
2,286.6900
--
Normalized EBITDA
-9,960.7790
-9,960.7790
-11,473.5980
-13,324.5420
-5,532.3840
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 12/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GYRE Gyre Therapeutics, Inc.
9.53
+0.53%
 
TRP.AX Tissue Repair Ltd
0.1950
-2.50%
 
EMBT Ember Therapeutics, Inc.
0.0001
0.00%
 
SNTI Senti Biosciences, Inc.
3.2600
-1.51%
 
26CA.MU ImmunityBio Inc
1.8800
+9.56%
 
BETRF BetterLife Pharma Inc.
0.0660
0.00%
 
ENGN enGene Holdings Inc.
2.9600
-12.68%
 
NUZ.AX Neurizon Therapeutics Limited
0.1400
0.00%
 
TYP.AX TRYPTAMINE FPO [TYP]
0.0340
+6.25%
 
ARGNF argenx SE
550.96
0.00%